Semaglutide type 1 diabetes use has moved into serious medical guidance, but the boundary is still clear: semaglutide is not approved to treat type 1 diabetes, and it does not replace insulin. The 2026 American Diabetes Association (ADA) Standards now tell clinicians to consider GLP-1 receptor agonists — medicines that copy a gut signal involved in appetite and blood sugar — as obesity treatment for some adults who have both conditions. Small trials are encouraging. They also show why the endocrinologist managing the insulin needs to steer the decision.
Semaglutide type 1 diabetes guidance changed in 2026
The change is guidance, not a new drug approval. The obesity section of the ADA's 2026 Standards of Care now includes GLP-1-based therapy among the treatment options for adults with type 1 diabetes and obesity, applying the same strategies used for other adults with obesity. It frames that as a shared decision between the person and their care team, not a default.
As of September 9, 2026, the day this article was written, specialist guidance had become more concrete. A paper in the September 2026 issue of Endocrinology and Metabolism Clinics of North America offers clinicians a step-by-step framework for selecting adults, monitoring glucose, and coordinating insulin changes (Saeed and Shah, 2026). Meanwhile, the 122-person phase 3 OBES1TY trial — a late-stage study — began on June 29, 2026. Its registry shows 68 weeks of treatment, with body weight as the main outcome and glucose range, insulin needs, low blood sugar, and ketones — acids that can build up when insulin is too low — among the other measures; the trial is recruiting and has no results yet.
That is real movement. It is not permission to treat type 1 diabetes with semaglutide as though it were type 2 diabetes.
What the ADJUST-T1D trial actually found
The trial behind much of this discussion was published online June 23, 2025, not 2026. ADJUST-T1D enrolled 72 adults with type 1 diabetes, obesity, and an automated insulin delivery system — a pump linked to a glucose sensor and software that adjusts insulin. For 26 weeks, half received semaglutide up to 1 mg weekly and half received an inactive placebo injection.
Its main outcome required three things at once: glucose between 70 and 180 mg/dL for more than 70% of the day, glucose below 70 for less than 4% of the day, and at least 5% weight reduction. In the NEJM Evidence trial, 36% of the semaglutide group reached all three goals, compared with 0% on placebo.
The average differences also favored semaglutide: 8.8 percentage points more time in range, a 0.3-percentage-point lower A1C — a roughly three-month measure of blood sugar — and 8.8 kg lower body weight versus placebo. Two severe low-blood-sugar events occurred in each group, and the researchers reported no diabetic ketoacidosis, or DKA, a dangerous acid buildup caused by too little insulin.
Those numbers are useful, but narrow. The study involved only adults with obesity who already used automated insulin delivery. Seventy-two people followed for six months cannot settle rare risks or tell us what happens across the much wider type 1 population.
Why the insulin finding matters so much
Semaglutide can reduce appetite and food intake while changing the amount of insulin a person needs. A May 2026 analysis of ADJUST-T1D found total daily insulin fell 22.6% in the semaglutide group by week 26. Mealtime insulin fell 30.5%, while background insulin fell 15.6% (Karakus et al., Diabetes Care 2026).
That isn't a home dosing formula. It is the reason the diabetes team has to watch the pump or injection plan closely. Too much insulin can cause hypoglycemia, meaning dangerously low blood sugar. Too little insulin can allow ketones to build up and lead to DKA.
The ADA guidance also covers dual GIP/GLP-1 medicines such as tirzepatide. GIP is another after-meal hormone signal. That class-level mention does not make tirzepatide interchangeable with semaglutide, and the ADJUST-T1D numbers do not transfer to it.
The risks go beyond nausea
Low blood sugar and ketosis sit at the center of the type 1 question. A separate 2025 crossover trial randomized 28 adults and had 24 finish both treatment periods. Semaglutide added an average 4.8 percentage points of time in the target glucose range without increasing time below range, but two people had recurrent euglycemic ketosis — ketone buildup even though glucose was not very high (Pasqua et al., Nature Medicine 2025). Neither developed DKA.
That small result is reassuring and cautionary at the same time. The ADJUST-T1D trial also had two severe hypoglycemia events in each group. Neither study was large enough to rule out uncommon harm.
Stomach problems matter differently here, too. Gastroparesis means the stomach empties unusually slowly, a complication that can already make meal insulin hard to time. The current FDA Ozempic label warns that hypoglycemia risk rises when semaglutide is combined with insulin and says Ozempic is not recommended in severe gastroparesis. The ADA says existing gastroparesis, impaired awareness of low blood sugar, or a recent episode of DKA should generally weigh against starting this drug class.
For the broader stomach, gallbladder, pancreas, kidney, and thyroid picture, see the full guide to semaglutide side effects.
What the new guidance does not mean
Semaglutide still cannot replace insulin. Type 1 diabetes involves little or no insulin production, and the ADA continues to describe insulin as essential treatment. The new recommendation is about obesity care alongside insulin, not treating the autoimmune disease itself.
It also does not apply the trial result to every person with type 1 diabetes. ADJUST-T1D required obesity and automated insulin delivery. The ADA obesity recommendation is likewise written for adults with type 1 diabetes and obesity. A person without obesity, with recent DKA, or with severe stomach-emptying problems is outside the clearest evidence.
Through Promise, semaglutide is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. The trials and brand labels do not establish that a compounded preparation is equivalent. Compounded semaglutide has its own regulatory and pharmacy distinctions. A licensed provider may still prescribe a compounded formulation; that decision is between you and your doctor.
The decision needs the diabetes team in the room
The practical question is not simply whether semaglutide can be prescribed. It is whether obesity treatment, insulin management, glucose monitoring, stomach symptoms, and ketone risk can be handled as one plan. An endocrinologist who can see the pump or injection data needs to be involved before and after any change.
Promise's intake asks about diabetes and insulin use for that reason. At Promise, a licensed provider reviews every request, and not everyone qualifies; type 1 diabetes or insulin use can lead the provider to decline. If treatment is prescribed, the medication comes from a licensed U.S. compounding pharmacy, but the endocrinology relationship remains essential.
The semaglutide visit is a medical review, not a guarantee of a prescription.
The evidence has moved from scattered off-label use toward clearer specialist guardrails. It has not moved semaglutide into the place insulin holds.